



S/N 09/701,945  
Invent No. ST980/4A

⑫

**EUROPEAN PATENT APPLICATION**

⑪ Application number: **93304103.0**

⑤1 Int. Cl.<sup>5</sup>: **C12N 15/57, C12N 9/64,  
C12Q 1/68**

⑫ Date of filing: **26.05.93**

The applicant has filed a statement in accordance with Rule 28 (4) EPC (issue of a sample only to an expert). Accession number(s) of the deposit(s): NRRL B-18971.

③0 Priority: **28.05.92 US 891542**

④3 Date of publication of application: **29.12.93 Bulletin 93/52**

⑧4 Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE**

⑦1 Applicant: **ELI LILLY AND COMPANY**  
**Lilly Corporate Center**  
**Indianapolis Indiana 46285 (US)**

⑦2 Inventor: **Dixon, Eric Paul**  
**4246 Bay Leaf Circle**  
**Indianapolis, Indiana 46237 (US)**  
Inventor: **Johnstone, Edward Marlon**  
**5129 East 69th Street**  
**Indianapolis, Indiana 46220 (US)**  
Inventor: **Little, Sheila Parks**  
**4480 North Meridian Street**  
**Indianapolis, Indiana 46208 (US)**  
Inventor: **Norris, Franklin Harpold**  
**5518 South Arlington Avenue**  
**Indianapolis, Indiana 46237 (US)**

⑦4 Representative: **Tapping, Kenneth George et al**  
**Erl Wood Manor**  
**Windlesham Surrey, GU20 6PH (GB)**  
**Declaration under Rule 28(4) EPC (expert solution)**

⑤4 **Protease and related DNA compounds.**

⑤7 This invention provides an amyloid precursor protein-cleaving protein and related nucleic acid compounds. The invention also provides methods, materials and assays. The compounds of this invention will further the characterization of neurological diseases such as Alzheimer's disease and Down's syndrome.

**EP 0 576 152 A1**

A peptide of 42 to 43 residues known as the  $\beta$ -amyloid peptide ( $\beta$ /A4) has been implicated in Alzheimer's disease and Down's syndrome. Researchers hypothesize that abnormal accumulation of this 4 kilodalton (kd) protein in the brain is due to cleavage of a larger precursor protein, called amyloid precursor protein (APP). Normal cleavage of APP occurs within the A4 region, indicating that an alternate cleavage event occurs when the normal full length is generated. The amino terminal residue of  $\beta$ /A4 is most often an aspartic acid (Asp), indicating that a protease which cleaves between the methionine (Met) at position 596 [Met<sub>596</sub> using the numbering system according to J. Kang, *et al.*, *Nature* 325:733 (1987).] and Asp<sub>597</sub> of APP would generate amyloid. Therefore, proteases which cleave the APP so as to generate  $\beta$ /A4 are important tools for characterizing Alzheimer's disease and Down's syndrome.

In the past, researchers have attempted to characterize the abnormal cleavage event through the use of classical protein purification techniques. These investigations have resulted in reports of a partially purified 68 kilodalton protease which cleaves at a Met-Asp bond of a synthetic peptide. C. Abraham, *et al.*, *Neurobiology of Aging* 11A:303 (1990). In 1991, Abraham and co-workers, compared the cleavage pattern of the 68 kd protease with known serine proteases. C. Abraham, *et al.*, *Biochemical and Biophysical Research Communications*, 174:790 (1991). Subsequently, the same researchers reported that the activity seen in the prior studies was actually the action of two independent proteases. One was identified as a calcium-dependent serine protease and the other a cysteine metalloprotease. C. Abraham, *et al.*, *Journal of Cellular Biochemistry*, 15:115 (1991); C. Abraham, *et al.*, *Journal of Neurochemistry*, 57:5109 (1991). No structure or characterization of these proteases was disclosed.

The present invention provides a new enzyme which is structurally different from those previously described and which will cleave APP to generate amyloidogenic fragments of the size expected of a Met<sub>596</sub>-Asp<sub>597</sub> cleavage. Thus, the new enzyme is very useful in furthering the characterization of Alzheimer's disease and Down's syndrome. Moreover, use of the invention may result in treatments for these or other related diseases.

To date there has been no satisfactory means of diagnosing Alzheimer's disease in a person until the dementia completely manifests itself. Confirmation of the dementia as having arisen from Alzheimer's disease requires a post-mortem examination of the brain of the afflicted patient. The instant invention provides a means of determining those patients having Alzheimer's disease or a propensity of developing Alzheimer's disease while such patients are still alive.

For purposes of clarity and as an aid in understanding the invention, as disclosed and claimed herein, the following items are defined below.

"293 cells" refers to a widely available transformed human primary embryonal kidney cell line, as described in F.L. Graham, *et al.*, *Journal of General Virology*, 36:59-72 (1977). This cell line may be obtained, for example, from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 10852-1776 (ATCC), under the accession number ATCC CRL 1573.

"AV12 cells" refers to another widely available cell line which may be obtained from the ATCC under the accession number ATCC CRL 9595.

"Amyloidogenic fragment" - An APP fragment comprising the  $\beta$ /A4 peptide.

"Functional compound of SEQ ID NO:1" - A compound comprising SEQ ID NO:1 which is capable of cleaving APP.

"Kunitz-like domain" - A protease inhibitor similar to soybean trypsin inhibitor or a nucleic acid sequence encoding a protease inhibitor which is similar to the soybean trypsin inhibitor. For example, the Kunitz Protease Inhibitor (KPI) region of APP as described in P. Ponte, *et al.*, *Nature* 331:525 (1988), or R.E. Tanzi, *et al.*, *Nature*, 331:528 (1988), or N. Kitaguchi, *et al.*, *Nature*, 331:530 (1988) is a Kunitz-like domain.

"pRc/Zyme" - A modified pRc/CMV eukaryotic expression vector, the pRc/CMV vector being available commercially (Invitrogen Corporation, 3985 Sorrento Valley Blvd., Suite B, San Diego, California 92121). The plasmid pRc/Zyme comprises a human cytomegalovirus promoter and enhancer, a bovine growth hormone polyadenylation signal, a neomycin resistance gene, a beta-lactamase gene useful as an ampicillin resistance marker in *E. coli*, and many other features as described in the 1991 Invitrogen Catalog, page 29, as well as a NotI/SalI insert of 1451 base pairs which contains an entire Zyme coding region.

"pSZyme" - A modified *E. coli* cloning vector pSPORT-1™ [described in E.Y. Chen, *et al.*, *DNA*, 4:165 (1985)], the plasmid pSPORT-1™ being commercially available (Gibco-BRL, 8400 Heigerman Court, Gaithersburg, Maryland 20877). This plasmid contains an origin of replication from a pUC vector, this plasmid being described in C. Yanisch-Perron, *et al.*, *Gene*, 33:103-119 (1985); the beta-lactamase gene which confers ampicillin resistance; a NotI/SalI insert of 1451 base pairs which contains an entire coding region of Zyme; as well as other features.

"Part of SEQ ID NO:1" - At least 6 consecutive amino acid residues of SEQ ID NO:1.

"mRNA" - ribonucleic acid (RNA) which has been transcribed either *in vivo* or *in vitro*, including, for example, RNA transcripts prepared *in vitro* by transcription of coding sequences of DNA by RNA polymerase.

"SEQ ID NO:1 or a functional equivalent thereof"

5 - SEQ ID NO:1 or a conservative alteration of the amino  
acid sequence of SEQ ID NO:1, wherein the conservative  
alteration results in a compound which exhibits  
10 substantially the same biological, biochemical, chemical,  
physical and structural qualities of SEQ ID:1.

"SEQ ID NO:3" - The DNA sequence ATG GCT GGC GGC  
ATC ATA GTC AGG G.

15 "SEQ ID NO:4" - The DNA sequence AAC CGA ATC TTC  
AGG TCT TCC TGG GG.

"SEQ ID NO:5" - The DNA sequence TCG CTC TCT CCT  
20 GGG GAC ACA GA.

"SEQ ID NO:6" -The DNA sequence CCA GGT GCT ATT CCA  
TGT ATG TCA TAG.

25 "SEQ ID NO:7" -The DNA sequence TCT GTG TCC CCA GGA  
GAG AGC GA.

"SEQ ID NO:8" -The DNA sequence ATA GTC AAG CTC TCT  
TCT CAA T.

30 "Transfection" - any transfer of nucleic acid into a host cell, with or without integration of said nucleic acid  
into genome of said host cell.

"Zyme" - the amino acid sequence SEQ ID NO:1 or a functional equivalent thereof.

35 "Zyme-related band configuration" - One of two band configurations chosen from two band configurations  
of a herein disclosed restriction fragment polymorphism. One pattern displays a 2400 base pair band, but no  
2500 base pair band. The other pattern displays a 2500 band, but no 2400 base pair band.

The present invention provides amino acid compounds which comprise the amino acid sequence

40 Met Lys Lys Leu Met Val Val Leu Ser Leu Ile Ala Ala Ala Trp Ala  
1 5 10 15

Glu Glu Gln Asn Lys Leu Val His Gly Gly Pro Cys Asp Lys Thr Ser  
20 25 30

45

50

55

5 His Pro Tyr Gln Ala Ala Leu Tyr Thr Ser Gly His Leu Leu Cys Gly  
                   35                  40                  45  
 Gly Val Leu Ile His Pro Leu Trp Val Leu Thr Ala Ala His Cys Lys  
           50                  55                  60  
 10 Lys Pro Asn Leu Gln Val Phe Leu Gly Lys His Asn Leu Arg Gln Arg  
       65                  70                  75                  80  
 Glu Ser Ser Gln Glu Gln Ser Ser Val Val Arg Ala Val Ile His Pro  
           85                  90                  95  
 15 Asp Tyr Asp Ala Ala Ser His Asp Gln Asp Ile Met Leu Leu Arg Leu  
           100                  105                  110  
 Ala Arg Pro Ala Lys Leu Ser Glu Leu Ile Gln Pro Leu Pro Leu Glu  
           115                  120                  125  
 20 Arg Asp Cys Ser Ala Asn Thr Thr Ser Cys His Ile Leu Gly Trp Gly  
       130                  135                  140  
 Lys Thr Ala Asp Gly Asp Phe Pro Asp Thr Ile Gln Cys Ala Tyr Ile  
       145                  150                  155                  160  
 25 His Leu Val Ser Arg Glu Glu Cys Glu His Ala Tyr Pro Gly Gln Ile  
           165                  170                  175  
 Thr Gln Asn Met Leu Cys Ala Gly Asp Glu Lys Tyr Gly Lys Asp Ser  
           180                  185                  190  
 30 Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Asp His Leu Arg  
           195                  200                  205  
 Gly Leu Val Ser Trp Gly Asn Ile Pro Cys Gly Ser Lys Glu Lys Pro  
       210                  215                  220  
 35 Gly Val Tyr Thr Asn Val Cys Arg Tyr Thr Asn Trp Ile Gln Lys Thr  
       225                  230                  235                  240  
 Ile Gln Ala Lys.  
                   244

hereinafter defined as SEQ ID NO:1, or a functional equivalent thereof. In particular, the amino acid compound which is SEQ ID NO:1 is preferred.

45 Those in the art will recognize that some alterations of SEQ ID NO:1 will fail to change the function of the amino acid compound. For instance, some hydrophobic amino acids may be exchanged for other hydrophobic amino acids, amino acids with similar side chains may be interchanged, basic amino acids may be interchanged with other basic amino acids, acidic amino acids may be interchanged with other acidic amino acids, small amino acids may be interchanged with other small amino acids or various other conservative changes may be made. Those altered amino acid compounds which confer substantially the same function in substantially
 50 the same manner as the exemplified amino acid compound are also encompassed within the present invention.

55 Artisans will also recognize that this protein can be synthesized by a number of different methods. All of the amino acid compounds of the invention can be made by chemical methods well known in the art, including solid phase peptide synthesis or recombinant methods. Both methods are described in U.S. Patent 4,617,149. Recombinant methods are preferred if a high yield is desired. A general method for the construction of any desired DNA sequence is provided in Brown, *et al.*, *Methods in Enzymology*, 68:109 (1979).

Other routes of production are well known. Expression in eucaryotic cells can be achieved via SEQ ID NO:2, described *infra*. For example, the amino acid compounds can be produced in eucaryotic cells using simian virus 40, cytomegalovirus, or mouse mammary tumor virus-derived expression vectors comprising DNA which encodes SEQ ID NO:1. As is well known in the art, some viruses are also appropriate vectors. For ex-

ample, the adenovirus, the vaccinia virus, the herpes virus, the baculovirus, and the rous sarcoma virus are useful. Such a method is described in U.S. Patent 4,775,624. Several alternate methods of expression are described in J. Sambrook, et al., Molecular Cloning: A Laboratory Manual, Chapters 16 and 17 (1989).

In another embodiment, the present invention encompasses nucleic acid compounds which comprise nucleic acid sequences encoding SEQ ID NO:1. As skilled artisans recognize, the amino acid compounds of the invention can be encoded by a multitude of different nucleic acid sequences due to the degeneracy of the genetic code, wherein most of the amino acids are encoded by more than one nucleic acid triplet. Because these alternate nucleic acid sequences would encode the same amino acid sequences, the present invention further comprises these alternate nucleic acid sequences. Preferably, the nucleic acid compound is DNA, sense or antisense mRNA. A most preferred embodiment of a DNA compound which encodes Zyme has this sequence:

	ATGAAGAAGC TGATGGTGGT GCTGAGTCTG ATTGCTGCAG CCTGGGCAGA	50
15	GGAGCAGAAT AAGTTGGTGC ATGGCGGACC CTGCGACAAG ACATCTCACC	100
	CCTACCAAGC TGCCCTCTAC ACCTCGGGCC ACTTGCTCTG TGGTGGGGTC	150
	CTTATCCATC CACTGTGGGT CCTCACAGCT GCCCACTGCA AAAAACCGAA	200
	TCTTCAGGTC TTCCTGGGGA AGCATAACCT TCGGCAAAGG GAGAGTTCCC	250
20	AGGAGCAGAG TTCTGTTGTC CGGGCTGTGA TCCACCCTGA CTATGATGCC	300
	GCCAGCCATG ACCAGGACAT CATGCTGTTG CGCCTGGCAC GCCCAGCCAA	350
	ACTCTCTGAA CTCATCCAGC CCCTTCCCCT GGAGAGGGAC TGCTCAGCCA	400
25	ACACCACCAG CTGCCACATC CTGGGCTGGG GCAAGACAGC AGATGGTGAT	450
	TTCCCTGACA CCATCCAGTG TGCATACATC CACCTGGTGT CCCGTGAGGA	500
	GTGTGAGCAT GCCTACCCTG GCCAGATCAC CCAGAACATG TTGTGTGCTG	550
	GGGATGAGAA GTACGGGAAG GATTCTGCC AGGGTGATTC TGGGGGTCCG	600
30	CTGGTATGTG GAGACCACCT CCGAGGCCCTT GTGTCATGGG GTAACATCCC	650
	CTGTGGATCA AAGGAGAAGC CAGGAGTCTA CACCAACGTC TGCAGATACA	700
	CGAACTGGAT CCAAAAAACC ATTCAGGCCA AG	732

which is hereinafter defined as SEQ ID NO:2. However, also preferred are those nucleic acid compounds which are sense and antisense mRNA.

Also provided by the present invention are nucleic acid vectors comprising nucleic acids which encode SEQ ID NO:1 or a functional equivalent thereof. The preferred nucleic acid vectors are those which are DNA. Most preferred are DNA vectors which comprise the DNA sequence which is SEQ ID NO:2. An especially preferred DNA vector is the plasmid pSZyme.

E. coli/pSZyme, which contains a cloning vector comprising SEQ ID NO:2, was deposited and made part of the stock culture collection of the Northern Regional Research Laboratories (NRRL), Agricultural Research Service, U.S. Department of Agriculture, Peoria, Illinois, 61604 on April 29, 1992, under the accession number NRRL B-18971. SEQ ID NO:2 can be isolated from the plasmid, for example, as a 1451 base pair NotI/SalI restriction fragment. Other fragments are useful in obtaining SEQ ID NO:2.

Additionally, the DNA sequences can be synthesized using commercially available automated DNA synthesizers, such as the ABS (Applied Biosystems, 850 Lincoln Centre Drive, Foster City, CA 94404) 380B DNA synthesizer. The DNA sequences can also be generated by the polymerase chain reaction (PCR) as described in U.S. Patent No. 4,889,818.

Restriction fragments of these vectors are also provided. The preferred fragments are the 1451 base pair NotI/SalI restriction fragment, the 803 base pair BsrBI/Esp3I restriction fragment and the 815 base pair EcoNI/BfaI restriction fragment of pSZyme.

Moreover, DNA vectors of the present invention preferably comprise a promoter positioned to drive expression of SEQ ID NO:2, or a functional equivalent thereof. Those vectors wherein said promoter functions in human embryonic kidney cells (293 cells), AV12 cells, yeast cells, or Escherichia coli cells are preferred. The DNA expression vector most preferred is plasmid pRc/Zyme.

The plasmid pSZyme, isolatable from E. coli using standard techniques, is readily modified to construct expression vectors that produce Zyme in a variety of organisms, including, for example, E. coli, yeast of the

family Saccharomycetes, and 293 cells derived from fall armyworm ovaries of the genus *Spodoptera*, (a commonly used host for baculovirus expression systems). [Commonly used references, such as Sambrook *et al.*, *supra*, describe these techniques.]

5 The current literature contains techniques for constructing AV12 expression vectors and for transfecting AV12 host cells. *See, e.g.*, U.S. Patent No. 4,992,373. The current literature also contains numerous techniques for constructing 293 expression vectors and for transfecting 293 host cells.

10 The construction protocols utilized for 293 cells can be followed to construct analogous vectors for other cell lines, merely by substituting, if necessary, the appropriate regulatory elements using well known techniques. Promoters which may be used, for example, include the thymidine kinase promoter, the metallothionin promoter, the heat shock promoter, immunoglobulin promoter, or various viral promoters such as the mouse mammary tumor virus promoter, SV40 promoter, herpesvirus promoters, or the BK virus promoters. In addition, artificially constructed promoters, derived from "consensus" sequences or created as hybrids of other promoters may be used in the course of practicing this invention.

15 The DNA compounds of the present invention also include primers and probes. Nucleic acid compounds of at least 18 consecutive base pairs which encode SEQ ID NO:1 or a part thereof are included in the present invention. Probes or primers which are DNA are preferred. Most preferred probes or primers are: SEQ ID NO:3 and SEQ ID NO:4. Those in the art will recognize the techniques associated with probes and primers as being well known.

20 For example, all or part of SEQ ID NO:3 or SEQ ID NO:4 may be used to hybridize to the coding sequence. The full length sequence can then be generated using polymerase chain reaction (PCR) amplification, using well known techniques. The full length sequence can be subsequently subcloned into any vector of choice.

Alternatively, SEQ ID NO:3 or SEQ ID NO:4 may be radioactively labeled at the 5' end in order to screen cDNA libraries by conventional means. Furthermore, any piece of Zyme-encoding DNA which has been bound to a filter may be saturated with total mRNA transcripts, in order to reverse transcribe the mRNA transcripts which bind.

Primers and probes may be obtained by means well known in the art. For example, once pSZyme is isolated, restriction enzymes and subsequent gel separation may be used to isolate the fragment of choice.

30 Another embodiment of the present invention is a genomic clone of Zyme. The preferred genomic clone is the 4.0 kilobase *HindIII* fragment from a human chromosome 19 library which hybridizes to fragments of DNA which encode SEQ ID NO:1. This can be obtained via hybridization with SEQ ID NO:2, or parts thereof. For example, SEQ ID NO:3 and SEQ ID NO:4 may be radioactively labelled and used to probe a chromosome 19 library, in order to then identify and isolate the corresponding genomic DNA.

The present invention also provides an Alzheimer's diagnostic assay wherein donor human DNA is:

- 35 1) digested with the restriction enzyme *Tag I*;  
2) hybridized with labelled Zyme DNA to reveal a Zyme-related band configuration; and  
3) compared to the similarly-digested and hybridized band configurations of those members of the donor's family who display or displayed the symptoms of Alzheimer's disease. The preferred Alzheimer's diagnostic assay utilizes a blood sample as the source of donor human DNA.

40 Since the genomic DNA is provided in the present invention and a Zyme-related restriction fragment length polymorphism is identified by the disclosure of this invention, the remainder of this procedure may be accomplished according to methods known in the art. For example, U.S. Patent 4,666,828, describes these procedures. [Numerous references, such as B. Lewin, *Genes*, at page 78 (1987), review restriction fragment length polymorphism techniques and theory.]

45 Host cells which harbor the nucleic acids provided by the present invention are also encompassed within this invention. A preferred host cell is an oocyte. A preferred oocyte is one which has been injected with sense mRNA or DNA compounds of the present invention. A still more preferred oocyte is one which has been injected with sense mRNA or DNA compounds of the present invention in conjunction with DNA or mRNA which encodes APP. Most preferred oocytes of the present invention are those which have been injected with sense mRNA.

50 Other preferred host cells are those which have been transfected with a vector which comprises SEQ ID NO:2. Preferred SEQ ID NO:2-transfected host cells include include 293, AV12, yeast and *E. coli* cells. Most preferred 293 and *E. coli* host cells are 293/pRc/Zyme, *E. coli*/pSZyme.

Also preferred is a host cell which has been co-transfected with a DNA vector which comprises SEQ ID NO:2 and a DNA vector which comprises the coding sequence of APP. 293 cells, AV12 cells, yeast cells and *E. coli* cells are especially useful co-transfected host cells.

55 An oocyte host cell can be constructed according to the procedure described in Lubbert, *et al.*, *Proceedings of the National Academy of Sciences (USA)*, 84:4332 (1987). DNA or RNA which encodes APP (both the 695 and 751 amino acid forms) may be obtained as described in Selkoe *et al.*, *Proceedings of the National Academy of Sciences (USA)*, 85:7341 (1988). Other host cell transfection is well known in the art. Co-transfection of cells

may be accomplished using standard techniques. See, e.g., Gorman et al., Molecular and Cellular Biology, 2:1044 (1982).

Therefore, the present invention also provides a process for constructing a host cell capable of expressing SEQ ID NO:1, said method comprising transfecting a host cell with a DNA vector that comprises a DNA sequence which encodes SEQ ID NO:1. A preferred method utilizes 293 cells as host cells. These 293 cells may be obtained from the ATCC under the accession number ATCC CRL 1573. Another preferred method utilizes AV12 cells as host cells. AV12 cells may be obtained from the ATCC under the accession number ATCC CRL 9595. Another preferred method utilizes yeast cells of the family *Saccharomycetes* or the bacterium *E.coli* as the host cells.

The preferred process utilizes an expression vector which comprises SEQ ID NO:2 in 293 cells. Especially preferred for this purpose is pRc/Zyme.

Another preferred process comprises (a) a DNA vector which comprises SEQ ID NO:2 and (b) a DNA expression vector which encodes the APP coding sequence. A most preferred process utilizes the DNA vector pRc/Zyme. Transfected host cells may be cultured under conditions well known to skilled artisans such that SEQ ID NO:1 is expressed, thus producing Zyme in the transfected host cell.

Additionally, the invention provides a process for identifying DNA homologous to a probe of the present invention, which comprises combining test nucleic acid with the probe under hybridizing conditions and identifying those test nucleic acids which hybridize. The preferred probes for use in this method are SEQ ID NO:3 and SEQ ID NO:4. Hybridization techniques are well known in the art. See, e.g., Sambrook, et al., *supra*.

Assays utilizing the compounds provided by the present invention are also encompassed within this invention. The assays provided determine whether a substance is a ligand for Zyme, said method comprising contacting Zyme with said substance, monitoring Zyme activity by physically detectable means, and identifying those substances which interact with or affect Zyme.

Preferred assays of the present invention incorporate a cell culture assay, a high performance liquid chromatography (HPLC) assay or a synthetic competition assay.

Preferred cell culture assays utilize oocytes, AV12, *E. coli*, yeast or 293 cells which co-express nucleic acids which encode Zyme and APP. Those co-expressing cell culture assays which are preferred include those which utilize 293/pRc/Zyme. A preferred assay utilizes yeast cells, and a DNA compound which encodes amino acids 587 to 606 of APP. One method of performing the yeast assay is described in Smith and Kohorn, Proceedings of the National Academy of Sciences, USA, 88:5159 (1991), using Zyme-encoding DNA and APP-encoding DNA which comprises the Met<sub>596</sub>/Asp<sub>597</sub> cleavage site codons.

Most preferred oocyte assays co-express mRNA. Most preferred cell culture assays utilize Western blot analysis or radiolabelled APP as the physically detectable means. A preferred HPLC assay is one wherein the substrate utilized is a full length, eukaryotically-derived APP.

The most preferred synthetic competition assay is one wherein the substance competes with the Kunitz-like domain gene product for binding to Zyme. The most preferred Zyme/Kunitz domain competition assay is one wherein APP is labelled with radioisotope.

The cell culture assays may be accomplished according to the procedures detailed by F. Ausubel, et al., Current Protocols in Molecular Biology, (1989) at pages 9.1-9.5. The HPLC assay may be performed essentially as described in Hirs and Timasheff, eds, Methods in Enzymology, Volume 91, Sections V and VI (1983). The Zyme/Kunitz-like domain binding or competition assay may be performed as described by J. Bennet and H. Yamamura, Neurotransmitter Receptor Binding, (1985) Chapter 3.

The present invention also provides a method for identifying or purifying Zyme, which comprises saturating test protein with anti-Zyme antibody, eliminating anti-Zyme antibody which fails to bind, and detecting the anti-Zyme antibody which remains bound. Antibody imaging techniques are known in the art.

The following are examples of aspects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

#### Example 1

##### Production of Zyme in 293 cells

A lyophilized aliquot of *E. coli* pSZyme can be obtained from the Northern Regional Research Laboratories, Peoria, Illinois, USA 61604, under the accession number NRRL B-18971 and used directly as the culture in the process described below. This culture has been deposited with the NRRL.

Plasmid pSZyme was isolated from a culture of *E. coli*/pSZyme by cesium chloride purification. Plasmid pSZyme was then digested with *Sall* and *NotI*. The resulting fragment was linear. DNA ligase was used to ligate this *Sall*-*NotI* fragment and a *Sall*-*HindIII* linker into a previously linearized pRc plasmid™. (Invitrogen, catalog

#V750-20)

Competent *E. coli* cells were then transfected with the newly created pRc/Zyme vector which contained SEQ ID NO:2 and selected for those cells which contained the ampicillin resistance gene by growing on ampicillin-containing medium.

After transfection of the pRc/Zyme vector into *E. coli*, a subsequent plasmid preparation was made in order to isolate the pRc/Zyme vector. In order to transfect 293 cells with the pRc/Zyme vector, the procedure developed by Chen and Okayama was employed. C. Chen and H. Okayama, *Molecular and Cellular Biology*, 7:2745 (1987). These cells were used in the cell culture assay as described in Example 2.

Selection on the antibiotic G418 (geneticin) was included in this step to produce stable transformants in 293 cells. The colonies which grew in the presence of G418 were then used as a source of Zyme.

## Example 2

### Cell Culture Assay

Human embryonic kidney cells (293 cells) were co-transfected with pRcZyme and an APP-encoding vector. On one occasion, a vector encoding the 695 amino acid APP (which lacks a Kunitz-like domain) was cotransfected with pRcZyme. On another occasion, a vector encoding the 751 amino acid APP (with the Kunitz-like domain) was cotransfected with pRcZyme.

Transfection was achieved using standard calcium phosphate transfection. Other transfection protocols, such as described by Sambrook, *et al.*, *supra*, are also effective. Amyloidogenic fragments were detected when the 695 amino acid (without KPI) APP coding sequence was used, via Western Blot analysis, as described in Sambrook, *et al.*, *supra*, using antisera to the carboxy-terminal amino acids of the APP protein. Anti BX6, as described in T. Oltersdorf, *et al.*, *Journal of Biological Chemistry*, 265:4492-4497 (1991), was used in this procedure. Amyloidogenic fragments were not detected when the 751 amino acid (with KPI) APP was used.

## Example 3

### HPLC Assay

Full length APP is produced in cells which have been infected with APP-encoding baculovirus. This procedure is accomplished according to J. Knops, *et al.*, *Journal of Biological Chemistry*, 266:7285 (1991). APP is then incubated in the presence of active Zyme and test compound. APP fragments are subsequently separated by high performance liquid chromatography. Each pooled fragment is then microsequenced using standard, such as those of Hirs and Timasheff, eds, *Methods in Enzymology*, Vol. 91 Sections V and VI, (1983). The quantity of amyloidogenic fragments (those which terminate at either Met<sub>696</sub> or ASP<sub>697</sub>) generated are compared to the quantity generated in the absence of test compound to determine the ability of the test compound to affect Zyme.

## Example 4

### Zyme/Kunitz-like Domain Competition Assay

A peptide representing the KPI domain of APP is synthesized and labelled with the isotope iodine-125 (<sup>125</sup>I). Competition binding assays are then conducted according to J.P. Bennet and H. Yamamura, *Neurotransmitter Receptor Binding* 61 (1985). Zyme is then bound to plastic microtitre wells as in the traditional ELISA assay. One such typical protocol for this step is described in F. Ausubel *et al.*, *Current Protocols in Molecular Biology*, 2:11.1-11.3 (1989). Radiolabelled KPI domain and unlabelled competitor compound is subsequently added to the wells of the 96-well microtitre plate. The wells are then washed. The remaining isotope is recorded in order to calculate the relative affinity of the unlabelled competitor compound to Zyme.

## Example 5

### Isolating the Genomic Clone

A genomic library specific for human chromosome 19 genomic library in Charon 21A bacteriophage was purchased from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, USA 20852, (ATCC) (Catalog number 57711). These phage were transfected into *E. coli* K802 *rec A*<sup>-</sup> host strain (Cat. no.

47026). The titre of the phage was  $6.5-7.0 \times 10^4$  plaque forming units per microliter. A genomic clone of the gene encoding Zyme was isolated by conventional screening of phage libraries (See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual 2.6-2.114, 1989).

A radiolabelled cDNA probe was synthesized utilizing the polymerase chain reaction (such as that described by Schowalter and Sommer, *Analytical Biochemistry*, 177:90-94, 1989) by specifically annealing SEQ ID NO: 5 and SEQ ID NO: 6 primers to an EcoRI/NotI purified (Bio-Rad Laboratories, P.O. Box 708, Rockville Centre, New York USA, 11571, catalog number 732-6010) pRc-Zyme DNA fragment.

Hybridization and washing was carried out at 65°C as described in the Zeta-Probe™ blotting membrane instruction manual (Bio-Rad, catalog number 164-0153). Putative primary Zyme bacteriophage were stored in SM buffer containing 2-3 drops of chloroform. A single homogenous plaque (711-4) was subsequently isolated from a tertiary screen. Isolation of lambda bacteriophage DNA positive by in situ hybridization to Zyme was accomplished using standard techniques.

Purified lambda phage Zyme DNA was digested with HindIII and electrophoresed on a 1% agarose/TBE (0.1 M Tris-HCl pH 8.3, 0.1 M boric acid, 1 mM ethylenediaminetetraacetic acid) gel. Separated DNA was then transferred onto a Zeta-Probe™ blotting membrane (0.5x TBE running buffer, constant 80 volts for 1 hour) as described in section 2.5 of the Zeta-Probe™ instruction manual using non-denaturing conditions, then denatured (0.4M NaOH for 10 minutes) as described in section 2.8 of the Zeta-Probe™ instruction manual.

A radiolabelled probe encompassing the BamHI/XbaI fragment of pRc/Zyme was used with a random primed DNA labelling kit (such as that which is commercially available by Boehringer Mannheim Corporation, 9115 Hague Road, P.O. Box 50414, Indianapolis, Indiana, USA 46250-0414, catalog number 1004760) to determine if the 3' coding sequence was found in our clone. Hybridization and washing to the above Zeta-Probe™ membrane was performed as previously described and autoradiography revealed homology to the 3' region of Zyme.

To confirm that phage 711-4 contained the 5' Zyme coding region, the polymerase chain reaction using SEQ ID NO:7 and SEQ ID NO:8 was again utilized to specifically amplify a 470 base pair band from tertiary plaque purified chromosome 19 Zyme phage DNA according to Kainz, et al., *Analytical Biochemistry*, 202:46 (1992). This DNA fragment was purified, then subcloned into the pUC 19 expression plasmid, described supra. The identity of the DNA sequences corresponding to sequences 1 to 33 of the 5' Zyme cDNA coding region and an additional 272 nucleotides upstream of the 5' Zyme coding region were confirmed by DNA sequence analysis, using standard techniques.

#### Plasmid Deposits

Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedures the following culture has been deposited with the permanent culture collection of the Northern Regional Research Center (NRRL), Agricultural Research Service, U.S. Department of Agriculture, 1815 N. University Street, Peoria, Illinois, 61604:

Deposited Material	Accession Number
<u>E. coli</u> K12/ pSZyme	NRRL B-18971

5

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: ELI LILLY AND COMPANY
- (ii) TITLE OF INVENTION: PROTEASE AND RELATED DNA COMPOUNDS
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: K. G. TAPPING
- (B) STREET: ERL WOOD MANOR
- (C) CITY: WINDLESHAM
- (D) STATE: SURREY
- (E) COUNTRY: UNITED KINGDOM
- (F) ZIP: GU20 6PH
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Diskette
- (B) COMPUTER: Macintosh
- (C) OPERATING SYSTEM: Macintosh 7.0
- (D) SOFTWARE: Microsoft Word

SEQ ID NO:1

Met Lys Lys Leu Met Val Val Leu Ser Leu Ile Ala Ala Ala Trp Ala  
 5 10 15  
 Glu Glu Gln Asn Lys Leu Val His Gly Gly Pro Cys Asp Lys Thr Ser  
 20 25 30  
 His Pro Tyr Gln Ala Ala Leu Tyr Thr Ser Gly His Leu Leu Cys Gly  
 35 40 45  
 Gly Val Leu Ile His Pro Leu Trp Val Leu Thr Ala Ala His Cys Lys  
 50 55 60  
 Lys Pro Asn Leu Gln Val Phe Leu Gly Lys His Asn Leu Arg Gln Arg  
 65 70 75 80  
 Glu Ser Ser Gln Glu Gln Ser Ser Val Val Arg Ala Val Ile His Pro  
 85 90 95  
 Asp Tyr Asp Ala Ala Ser His Asp Gln Asp Ile Met Leu Leu Arg Leu  
 100 105 110  
 Ala Arg Pro Ala Lys Leu Ser Glu Leu Ile Gln Pro Leu Pro Leu Glu  
 115 120 125  
 Arg Asp Cys Ser Ala Asn Thr Thr Ser Cys His Ile Leu Gly Trp Gly  
 130 135 140  
 Lys Thr Ala Asp Gly Asp Phe Pro Asp Thr Ile Gln Cys Ala Tyr Ile  
 145 150 155 160  
 His Leu Val Ser Arg Glu Glu Cys Glu His Ala Tyr Pro Gly Gln Ile  
 165 170 175  
 Thr Gln Asn Met Leu Cys Ala Gly Asp Glu Lys Tyr Gly Lys Asp Ser  
 180 185 190  
 Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Asp His Leu Arg  
 195 200 205  
 Gly Leu Val Ser Trp Gly Asn Ile Pro Cys Gly Ser Lys Glu Lys Pro  
 210 215 220  
 Gly Val Tyr Thr Asn Val Cys Arg Tyr Thr Asn Trp Ile Gln Lys Thr  
 225 230 235 240  
 Ile Gln Ala Lys  
 244

5 SEQ ID NO:2

ATGA AGAAGCTGAT 14  
 GGTGGTGTCTG AGTCTGATTG CTGCAGCCTG GGCAGAGGAG CAGAATAAGT TGGTGCATGG 74  
 CGGACCCTGC GACAAGACAT CTCACCCCTA CCAAGCTGCC CTCTACACCT CGGGCCACTT 134  
 GCTCTGTGGT GGGGTCCTTA TCCATCCACT GTGGGTCCTC ACAGCTGCCC ACTGCAAAAA 194  
 10 ACCGAATCTT CAGGTCTTCC TGGGGAAGCA TAACCTTCGG CAAAGGGAGA GTTCCCAGGA 254  
 GCAGAGTTCT GTTGTCCGGG CTGTGATCCA CCCTGACTAT GATGCCGCCA GCCATGACCA 314  
 GGACATCATG CTGTTGCGCC TGGCAGGCC AGCCAACTC TCTGAACTCA TCCAGCCCCT 274  
 TCCCCTGGAG AGGGACTGCT CAGCCAACAC CACCAGCTGC CACATCCTGG GCTGGGGCAA 334  
 GACAGCAGAT GGTGATTTC CTGACACCAT CCAGTGTGCA TACATCCACC TGGTGTCCCG 394  
 TGAGGAGTGT GAGCATGCCT ACCCTGGCCA GATCACCAG AACATGTTGT GTGCTGGGGA 454  
 15 TGAGAAGTAC GGAAGGATT CCTGCCAGGG TGATTCTGGG GTTCCGCTGG TATGTGGAGA 514  
 CCACCTCCGA GGCCTTGTGT CATGGGGTAA CATCCCTGT GGATCAAAGG AGAAGCCAGG 574  
 AGTCTACACC AACGTCTGCA GATACACGAA CTGGATCCAA AAAACCATTC AGGCCAAG 632

SEQ ID NO:3

20 ATG GCT GGC GGC ATC ATA GTC AGG G 25

SEQ ID NO:4

AAC CGA ATC TTC AGG TCT TCC TGG GG 26

25 SEQ ID NO:5

TCG CTC TCT CCT GGG GAC ACA GA 23

SEQ ID NO:6

30 CCA GGT GCT ATT CCA TGT ATG TCA TAG 27

SEQ ID NO:7

TCT GTG TCC CCA GGA GAG AGC GA 23

35 SEQ ID NO:8

ATA GTG AAG CTG TCT TCT CAA T 22

40

# Claims

45

1. An amino acid compound which comprises the amino acid sequence

50

55

5 Met Lys Lys Leu Met Val Val Leu Ser Leu Ile Ala Ala Ala Trp Ala  
 1 5 10 15  
 Glu Glu Gln Asn Lys Leu Val His Gly Gly Pro Cys Asp Lys Thr Ser  
 20 25 30  
 His Pro Tyr Gln Ala Ala Leu Tyr Thr Ser Gly His Leu Leu Cys Gly  
 35 40 45  
 10 Gly Val Leu Ile His Pro Leu Trp Val Leu Thr Ala Ala His Cys Lys  
 50 55 60  
 Lys Pro Asn Leu Gln Val Phe Leu Gly Lys His Asn Leu Arg Gln Arg  
 65 70 75 80  
 15 Glu Ser Ser Gln Glu Gln Ser Ser Val Val Arg Ala Val Ile His Pro  
 85 90 95  
 Asp Tyr Asp Ala Ala Ser His Asp Gln Asp Ile Met Leu Leu Arg Leu  
 100 105 110  
 20 Ala Arg Pro Ala Lys Leu Ser Glu Leu Ile Gln Pro Leu Pro Leu Glu  
 115 120 125  
 Arg Asp Cys Ser Ala Asn Thr Thr Ser Cys His Ile Leu Gly Trp Gly  
 130 135 140  
 25 Lys Thr Ala Asp Gly Asp Phe Pro Asp Thr Ile Gln Cys Ala Tyr Ile  
 145 150 155 160  
 His Leu Val Ser Arg Glu Glu Cys Glu His Ala Tyr Pro Gly Gln Ile  
 165 170 175  
 30 Thr Gln Asn Met Leu Cys Ala Gly Asp Glu Lys Tyr Gly Lys Asp Ser  
 180 185 190  
 Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Gly Asp His Leu Arg  
 195 200 205  
 35 Gly Leu Val Ser Trp Gly Asn Ile Pro Cys Gly Ser Lys Glu Lys Pro  
 210 215 220  
 Gly Val Tyr Thr Asn Val Cys Arg Tyr Thr Asn Trp Ile Gln Lys Thr  
 225 230 235 240  
 40 Ile Gln Ala Lys  
 244  
 45

hereinafter defined as SEQ ID NO:1, or a functional equivalent thereof.

2. A nucleic acid compound which comprises an nucleic acid sequence which encodes for a compound of Claim 1 or a part thereof.

3. A nucleic acid compound as claimed in Claim 2 which comprises the sequence

ATGAAGAAGC TGATGGTGGT GCTGAGTCTG ATTGCTGCAG CCTGGGCAGA 50  
 5 GGAGCAGAAT AAGTTGGTGC ATGGCGGACC CTGCGACAAG ACATCTCACC 100  
 CCTACCAAGC TGCCCTCTAC ACCTCGGGCC ACTTGCTCTG TGGTGGGGTC 150  
 CTTATCCATC CACTGTGGGT CCTCACAGCT GCCCACTGCA AAAAACCAGAA 200  
 TCTTCAGGTC TTCCTGGGGA AGCATAACCT TCGGCAAAGG GAGAGTTCCC 250  
 10 AGGAGCAGAG TTCTGTTGTC CGGGCTGTGA TCCACCCTGA CTATGATGCC 300  
 GCCAGCCATG ACCAGGACAT CATGCTGTTG CGCCTGGCAC GCCCAGCCAA 350  
 ACTCTCTGAA CTCATCCAGC CCCTTCCCCCT GGAGAGGGAC TGCTCAGCCA 400  
 15 ACACCACCAG CTGCCACATC CTGGGCTGGG GCAAGACAGC AGATGGTGAT 450  
 TTCCCTGACA CCATCCAGTG TGCATACATC CACCTGGTGT CCCGTGAGGA 500  
 GTGTGAGCAT GCCTACCCTG GCCAGATCAC CCAGAACATG TTGTGTGCTG 550  
 GGGATGAGAA GTACGGGAAG GATTCTTGCC AGGGTGATTG TGGGGGTCCG 600  
 20 CTGGTATGTG GAGACCACCT CCGAGGCCTT GTGTGATGGG GTAACATCCC 650  
 CTGTGGATCA AAGGAGAAGC CAGGAGTCTA CACCAACGTC TGCAGATACA 700  
 CGAACTGGAT CCAAAAAACC ATTCAGGCCA AG 732

25

or a functional equivalent or part thereof.

4. A nucleic acid vector which comprises the nucleic acid compound of Claim 3.
- 30 5. A DNA vector of Claim 4 which is pSZyme.
6. A host cell transfected with a nucleic acid vector of Claim 4.
7. A genomic clone of Zyme which comprises a 4.0 kilobase HindIII fragment from a human chromosome 19 library which hybridizes to fragments of DNA of the compound of claim 3 under conditions suitable for selective hybridization.
- 35 8. A process for diagnosing Alzheimer's disease or a propensity to develop Alzheimer's disease in a patient which comprises
  - a) securing DNA from said patient;
  - 40 b) digesting said DNA with a restriction enzyme;
  - c) hybridizing said digested DNA with a labeled nucleotide sequence corresponding to the compound of SEQ ID NO:2, or a part thereof; and
  - d) comparing pattern of hybridization to similarly-digested and hybridized band configurations of those members of the donor's family who display or have displayed the symptoms of Alzheimer's disease.
- 45 9. An assay for determining whether a test substance is a functional ligand for a protein of SEQ ID NO:1, said method comprising
  - a) contacting the protein with said test substance;
  - b) monitoring the protein's activity by physically detectable means; and
  - 50 c) identifying those substances which interact with or affect the activity of the protein relative to a control which receives no test substance.
- 55 10. A method for expressing a nucleic acid sequence as claimed in Claim 2 in a transfected host cell, said method comprising culturing said transfected host cell under conditions suitable for gene expression.

European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 93 30 4103

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	WO-A-9 207 068 (ATHENA NEUROSCIENCES, INC. ET AL.) * the whole document * ---	1-6,9-10	C12N15/57 C12N9/64 C12Q1/68
A	WO-A-9 203 542 (BOSTON UNIVERSITY) * the whole document * ---	1,9	
D,A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 174, no. 2, 31 January 1991, NEW YORK, US pages 790 - 796 C.R. ABRAHAM ET AL. 'A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid beta-protein' * the whole document * ---	1	
A	WO-A-9 200 374 (E.I. DU PONT DE NEMOURS AND COMPANY) * the whole document * ---	1,9	
A	WO-A-9 113 904 (CEPHALON, INC.) * the whole document * -----	1-6,9	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.5)  C12N C12Q
Place of search BERLIN		Date of completion of the search 11 AUGUST 1993	Examiner JULIA P.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- A : member of the same patent family, corresponding document	

EPO FORM 1500 (04/92) (P0001)